Changing Inequalities in Cervical Cancer: Modeling the Impact of Vaccine Uptake, Vaccine Herd Effects, and Cervical Cancer Screening in the Post-Vaccination Era

  title={Changing Inequalities in Cervical Cancer: Modeling the Impact of Vaccine Uptake, Vaccine Herd Effects, and Cervical Cancer Screening in the Post-Vaccination Era},
  author={Tal{\'i}a Malag{\'o}n and Mélanie Drolet and Marie-Claude Boily and J. F. Laprise and Marc Brisson},
  journal={Cancer Epidemiology, Biomarkers \& Prevention},
  pages={276 - 285}
Background: Inequalities in cervical cancer may be increased following mass vaccination against the human papillomavirus (HPV) if girls with low vaccine uptake also have low future participation in cervical cancer screening. We evaluated how vaccine uptake distribution affects inequalities in squamous cell carcinoma (SCC) incidence between groups with different screening participation. Methods: We used an individual-based transmission dynamic model of HPV infection and disease (HPV-ADVISE… 

Figures and Tables from this paper

Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review

Policy makers making recommendations for cervical cancer screening will have to consider HPV vaccination coverage and herd effects, as these will affect the positive predictive value of screening and the risk of cervical cancer in unvaccinated women.

The borders that remain: prevention of cervical cancer in refugee and immigrant women in Canada

Preventative health care initiatives should consider the barriers specific to the population at which they are aimed, and work in close collaboration with multidisciplinary settlement services.

Human Papillomavirus Vaccination: Making Sense of the Public Controversy

A large body of evidence supports the prevailing scientific opinion that human papillomavirus (HPV) vaccines are efficacious, safe, and cost-effective. Since first licensure in 2006, however, HPV

An empirical study of the ‘underscreened’ in organised cervical screening: experts focus on increasing opportunity as a way of reducing differences in screening rates

Experts emphasised the provision of opportunity for underscreened populations to take up screening, and appeared to rely on tacit premises not supported by evidence: that provision of meaningful opportunity leads to increased uptake, and that increased uptake of an initial screening test by disadvantaged populations would decrease cervical cancer incidence and mortality.

Deaths from Cancer

Cartograms highlight that urban areas, particularly the Tokyo and Osaka metropolitan areas, have higher SMRs for female breast, lung, oesophageal and ovarian cancer, and that lung cancer mortality has shown the widest absolute inequalities for both sexes recently.



Association between human papillomavirus vaccine uptake and cervical cancer screening in the Netherlands: Implications for future impact on prevention

The results show that vaccination status was significantly associated with mothers' screening participation, which resulted in slightly lower model estimates of the impact of vaccination on cancer incidence, compared to estimates assuming no association.

Sociodemographic Inequalities in Sexual Activity and Cervical Cancer Screening: Implications for the Success of Human Papillomavirus Vaccination

The success of human papillomavirus vaccination at reducing cervical cancer and inequalities will depend on achieving high coverage among high-risk subpopulations, and groups must be monitored closely, and if need be, targeted for additional interventions.

Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services

The results of a cross-sectional survey of young women attending sexual health services (SHS) in England report lower vaccination offer and completion rates and higher prevalence of HPV-related risk factors compared with national data.

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

Within 4 years of vaccine introduction, the vaccine-type HPV prevalence decreased among females aged 14-19 years despite low vaccine uptake, and the estimated vaccine effectiveness was high.

Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study.

Investigation of factors associated with HPV vaccine initiation and completion within the routine HPV vaccination programme in the South West of England found associations with ethnicity and substantially lower uptake in non-mainstream educational settings were observed.

Human papillomavirus vaccine introduction--the first five years.